Should Plavix Be Avoided By Those Using Prilosec? Yes, Says the FDA
Last November 17th, 2009, the F. D. A. issued a warning on a commonly prescribed anti-clotting drug, commonly labeled as “Plavix.” Some consumers are asking if Plavix is a medication to be avoided. In short, the word is, not unless the patient is also using “Prilosec” Brand stomach acid reducer.
The F.D. A.'s own website points out that consumers using Prilosec and Plavix together are preventing the effectiveness of the Plavix in the first case.
Plavix is used to prevent clotting. This happens, once the medication is metabolized by the same enzyme, blocked by Prilosec. The crux of the problem – on a pharmo-bio-mechanical level is, the enzyme itself. In one case it's an agent of effect, and in the other, the enemy.
Since the effectiveness of Plavix is dependant upon the enzyme to metabolize it. The patient misses half of the help of the medication projected, left with a higher heart attack risk. Consumers should expect to see updates from the F. D. A. on labels of both/either products shortly.
Other drugs, with similar molecular construct to the Prilosec brand, and therefore possibly similar problems, include Nexium (esomeprazole), Tagamet and Tagamet HB (cimetidine), Diflucan (fluconazole), Nizoral (ketoconazole), VFEND (voriconazole), Intelence (etravirine), Felbatol (felbamate), Prozac, Serafem, Symbyax (fluoxetine), Luvox (fluvoxamine) and Ticlid (ticlopidine).
Either drug seems fine, it's the combination, always a point to watch
Outside of total contraindication of combination, no other factors had any effect during the most recent studies conducted by manufacturers of Plavix, Sanofi-Aventis, and Bristol Myers-Squibb. Company representatives also vow to continue research into any other possible interactions with other enzyme-blocking prescriptions.
Is this research going to affect the costs of prescriptions?
While it's obvious the additional research might cut into company profits initially, the liabilities prevented will assure a fair roi for shareholders, in spite of the “alert” nature of the news, from the F. D. A. It is, after, not just their livelihoods here. It's a patient's life.
Could there be another approach to the problem for patients?
Proponents of “alternative” methods of “holistic health” often recommend a lifestyle that causes less scarring of the arteries in the first place, therefore preventing the fear of cholesterol pre-emptively. Such decisions can only be made with the consultation of a trusted, licensed physician, and nothing in this editorial should be seen as replacement of the advice of a doctor.